MEDBOT-B's stock surged 5.24% during intraday trading on Thursday, reflecting strong investor sentiment toward the surgical robotics company.

The rally was driven by multiple positive developments. UBS recently upgraded its rating on the stock from "Neutral" to "Buy" and significantly raised its target price, citing robust overseas sales potential and projecting strong revenue and earnings growth over the next three years. The company also targets doubling its total revenue year-over-year, with overseas revenue expected to contribute over 80% of the total.

Additionally, the company achieved a significant milestone with its self-developed Honghu orthopedic surgical robot obtaining European CE certification, marking it as the first domestically developed joint replacement surgical robot to receive such approval. Supportive policies from Beijing and Hunan regarding surgical robot hospital adoption and reimbursement standards provided further momentum for the sector.